ONCOLOGICAL TREATMENT OF PENILE CANCER FROM THE POINT OF VIEW OF RADIATION ONCOLOGIST
Authors:
Hana Stankušová
Authors place of work:
Onkologická klinika 2. LF UK a FN Motol, Praha
Published in the journal:
Ces Urol 2015; 19(1): 19-32
Category:
Review article
Summary
Penile cancer is a rare tumour, however it has serious psychological and social consequences.The incidence of penile cancer increases with reaching with maximum in the sixth decade of life. The aetiological and epidemiological penile cancer risk factors are well recognized. Among them human papilloma virus infection, namely types HPV 16 and 18 is an important. Due to its low incidence about 1/100 000, there is limited experience with penile cancer therapy in most of urology or oncology departments. Randomised prospective studies are not available. Reports about surgical and other oncological therapy describe small studies with patients treated during long period. Early surgical treatment of penile lesions, and if possible of nodal metastases, plays an essential role in curing the disease and its prognosis. The review article highlights the importance of precise diagnosis and staging for the stratification of the patients and selection appropriate therapy according to risk and prognostic factors. The role of contemporary radiotherapy and chemotherapy in multimodal treatment of penile cancer is discussed. Additionally, personal experience with HDR brachytherapy in the treatment of 25 patients is discussed.
KEY WORDS:
Penile cancer, radiotherapy, brachytherapy, chemotherapy.
Zdroje
1. Novák J, Žídek I. Carcinoma of the penis. Praha: Grada Publishing, 1996.
2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: Globocan 2008, Int J Cancer 2010; 127: 2893–2917.
3. Dilner J, van Krogh G, Horenblas, et al. Etiology of squamous call carcinoma of the penis. Scand J Urol Nephrol Suppl 2000; (205): 189–193.
4. Maden C, Sherman KJ, Beckmann AM, et al. History of circumcision, medical conditions, and sexual activity and risk of penile cancer. JNatl Cancer Inst 1993 Jan; 85(1): 19–24.
5. Archier E, Devaux S, Castela E, et al. Carcinogenic risk of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venerol 2012 May; (26 suppl 3): 22–31.
6. Philippou P, Shabir M, Ralph DJ, et al. Genital lichen sclerosus/balanitis xerotica obliterans/in men with penile carcinoma: a critical analysis. BJU Int 2013 May; 111(6): 970–976.
7. Bleeker MCG, Heideman DAM, Snijders PJF, et al. Penile cancer: Epidemiology, pathogenesis and prevention. World J of Urology 2008; 27(2): 141–150.
8. Backes DM, Kurman RJ, Pimenta JM, et al. Systematic review of human papilomavirus prevalence in invasive penile cancer. Cancer causes Contro1 2009 May; 20(4): 449–457.
9. Michal M, Hes O, Kacerovska D, et al. Klasifikace intraepiteliálních neoplazií předcházejících dlaždicovému karcinomu penisu a jejich analogie s rekancerózami dlaždicových karcinomů vulvy. Ces Urol 2014, 18(2): 94–100.
10. Lont AP, Kroon BK, Horenblas S, et al. Presence of high risk human papilllomavirus DNA in penis carcinoima predicts favorable outcome in surfoval. Int J Cancer 2006 Sep; 119(5): 1078–1081.
11. Bezerra AL, Lopes A, Santiago GH, et al. Human papilomavirus as a prognostic factor in carcinoma of penis: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. Cancer 2001 Jun; 91(12): 5–21.
12. Rubin MA, Kleter B, Zhou M, et al. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol 2001; 159: 1211–1218.
13. Schneider H, Sokol L, Valanský L, et al. Verukózny karcinom penisu – zriedkavý variant dlaždicobunkového karcinómu. Ces Urol 2000; 4(2): 43–46.
14. Velazquez EF, Barreto JE, Rodriquez I, et al. Limitations in the interpretation of biopsies in patiens with penile squamous cell carcinoma. Int J Surg Pathol 2004 Apr; 12(2): 139–146.
15. TNM klasifikace zhoubných novotvarů. 7. vydání 2009 (česká verze 2011); ÚZIS 93–95.
16. Kayes O, MinhasS, AllenC, et al. The role of magnetic resonance imaging in the local staging of penile cancer. European Urology 2007; Vol 51(5): 1313–1319.
17. Hora M, Trávníček I, Kalusová K, et al. Penis šetřící metody léčby nižších T kategorií karcinomu penisu Ces Urol 2014, 18(3): 199–207.
18. Babjuk M, Novák J, Dvořáček J. Nd: YAG Laser v léčbě povrchových lézí penisu Rozhledy Chir, 1998; 77: 497–499.
19. Alexiades-Armenakas MR, Dover JS, Arndt KA. Fractional laser skin resurfacing. Journal Journal of drugs in dermatology: JDD 2012; 11(11): 1274–1287.
20. Meijer RP, BoonTA, vanVenrooij GE, et al. Long-term follow up after laser therapy for penile carcinoma.Urology 2007 Apr; 69(4): 759–762.
21. Hora M, Pizinger K, Bursa V, et al. Glansektomie v léčbě karcinomu penisu. Ces Urol 2011; 15(1): 15–23.
22. Hakenberg OW, Compérat E, Minhas S, et al. Guidelines on penile cancer, EAU 2014.
23. Pávek V, Drábek M, Lavička Z. Lymfadenektomie sentinelové uzliny epidermoidního karcinomu prostaty. Ces Urol 2012, 16(2): 125–128.
24. National Institute for Clinical Excellence (2002) Guidance on cancer services. Improving outcomes in urological cancers- the manual. NICE, London: 83–85, také: http://www.nice, org, uk/pdfúUrological_Manual. pdf.
25. Azif M, Logue JP, Swindell R, et al. External – beam radiotherapy in T1–T2 N0 penile carcinoma. Clinical Oncology May 2006; 18(4): 320–325.
26. Franks KN, Kancherla K, Sethugavalar B, et al. Radiotherapy for node positive penile cancer: experience of the Leeds teaching hospitals. J. Urol 2011 Aug; 186(2): 524–529.
27. Chaudhari AJ, Ghosh S, Bhalavat RL, et al. Interstitial brachytherapy in carcinoma of penis. Strahlenth Oncol 1999; 175: 17–20.
28. Delannes M, Malavaud V, Douchez J, et al. Iridium-192 interstitial radiation therapy for squamous cell carcionoma of the penis. Int J Radiat Oncol Biol Phys 1984; 10: 1891–1895.
29. Gerbaulet A, Lambin P, Haie-Mader C, et al. Brachytherapy of penile cancer. Ann Urol 1994; 28: 306–311.
30. Kanfir K, Haie-Mader C, Abano M, et al. Outcome of patiens treated with exclusive brachytherapy for carcinoma of penis: the IGR experience. Clin Oncol 2000; 12: 25–31
31. Kiltie AE, Elwell C, Close HJ, et al. Iridium-192 implantation for node-negative carcinoma of the penis. Clin Oncol 2000; 12: 25–31.
32. Mazeron JJ, Langlois D, Lobo PA, et al. Interstitial radiation therapy for carcinoma of the penis using iridium -192 wires. The Henri Mondor experience (1970–1979) Int J Radiat Oncol Biol Phys 1984; 10: 1891–1895.
33. Rozan R, Albuisson E, Giraud B, et al. Interstitial brachytherapy for penile carcinoma; a multicentric survey (259 patients), Radiother Oncol 1995; 36: 83–93.
34. Suchaud JP, Kantor G, Richard P, et al. Brachytherapy of the cancer of the penis. Analysis of a series of 53 cases. J Urol 1989; 95: 27–31.
35. Crook JM, Haie-Meder C, Demanes DJ, et al. American Brachytherapy Society-Groupe Europeén de Curiethérapie- European Society of Therapeutic Radiation Oncology (ABC-GEC-ESTRO) consensus statement for penile brachytherapy. Brachytherapy 2013; 12: 191–198.
36. Petera J, Odrazka K, Zouhar M, et al. High-dose rate interstitial brachytherapy for the treatment of penile carcinoma. Strahhlenter Oncol 2004; 180: 123–125.
37. Pagliaro LC, Williams DL, Daliani D, et al. Neoadjuvant paclitaxel, ifosfamid, and cisplatin chemotherapy for metastatic penile cancer: A phase II study. J Clin Oncol, 2010; (28)24: 3851–3857.
38. Ahmed T, Sklarof R, Yagoda A. An appraisal of the efficacy of bleomycin in epidermoid carcinoma of the penis. Anticancer res 1984; 4: 289–292.
39. Garnick MB, Skarin AT, Steele GD. Metastatic carcinoma of the penis: complete remission after high dose methotrexate chemotherapy. J Urol 1979; 122: 265–266.
40. Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol 1992; 147: 630–632.
41. Theodore C, Skoneczna I, Bodrogi I, et al. A phase II multicentre study of irinotecan in combination with cisplatin in metastatic or locally advanced penile carcinoma (EORTC protocol 30992). Ann Oncol 2008; 19: 1304–1307.
42. Kattan J, Culine S, Droz JP, et al. Penile cancer chemotherapy: Twelve years experience at Institut Gustave-Roussy. UROLOGY 1993; 42(5): 559–563.
43. Pizzocaro G, Piva L, Bandieramonte G, et al. Up-to-date management of carcinoma of the penis. Eur Urol 1997; 32: 5–15.
44. Dexeus FH, Logothetis CJ, Sella A, et al. Combination of chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract. J Urol 1991; 146: 1284–1287.
45. Bermejo C, Busby JE, Spiess PE, et al. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urol 2007; 177: 1335–1338.
46. DiLorenzo G, Federico P, Buonerba C, et al. Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur Urol 2011; 60: 1280–1284.
47. Pizzocaro G, Nicolai N, Milani A. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol 2009; 55: 546–551
Štítky
Paediatric urologist Nephrology UrologyČlánok vyšiel v časopise
Czech Urology
2015 Číslo 1
Najčítanejšie v tomto čísle
- IMMUNOSTIMULATION WITH POLYBACTERIAL LYSATE (URIVAC®) IN PREVENTING RECURRENT LOWER URINARY TRACT INFECTIONS
- COMPLICATIONS FOLLOWING LOCAL APPLICATION OF INORGANIC MATERIAL INTO THE SUBCUTANEOUS TISSUE OF PENIS
- ONCOLOGICAL TREATMENT OF PENILE CANCER FROM THE POINT OF VIEW OF RADIATION ONCOLOGIST
- EMPHYSEMATOUS PYELONEPHRITIS – DESCRIPTION OF SIX CASES